Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by DICE Therapeutics, Inc.

DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics to Participate at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics to Present at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Announces Pricing of Upsized Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Announces Proposed Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
From DICE Therapeutics, Inc.
Via GlobeNewswire
Tickers DICE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.